
    
      This is a prospective and retrospective study of a population of patients with mutated
      non-small cell lung cancer in the Nord Pas de Calais. Retrospective cohort will involve
      patients with main molecular abnormalities, identifiable from molecular biology platform
      CRRC, except EGFR and KRAS treated from September 2011 to February 2013.
    
  